RATIONALE: Giving monoclonal antibodies, such anti-CD45 monoclonal antibody and alemtuzumab, and chemotherapy drugs, such as fludarabine, before a donor stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
PURPOSE: This phase I trial is studying the side effects and how well giving anti-CD45 monoclonal antibody together with alemtuzumab and fludarabine followed by donor stem cell transplant works in treating patients with severe combined immunodeficiency disease or other primary immunodeficiency disorder.
Primary Outcome Measures:
- T-cell function [ Designated as safety issue: No ]
- B-cell function [ Designated as safety issue: No ]
- Donor hematopoiesis [ Designated as safety issue: No ]
- Toxicity [ Designated as safety issue: Yes ]
- Incidence of grade III-IV acute graft-versus-host disease [ Designated as safety issue: Yes ]
- 1-year survival rate [ Designated as safety issue: No ]
Estimated Enrollment: |
21 |
Study Start Date: |
December 2007 |
Estimated Primary Completion Date: |
December 2013 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- To investigate whether anti-CD45 monoclonal antibody, alemtuzumab, and fludarabine followed by allogeneic stem cell transplantation using CD34+ selected cells promotes donor stem cell engraftment sufficient to provide T-cell function and B-cell function and to establish donor hematopoiesis in pediatric patients with severe combined immunodeficiency disease or other primary immunodeficiency disorder.
- To investigate whether this treatment regimen can be given with minimal and acceptable short term toxicity.
- To investigate the incidence of grade III-IV acute graft-versus-host disease in patients treated with this regimen.
- To estimate the 1-year survival of patients treated with this regimen.
OUTLINE: Patients receive alemtuzumab IV on days -8 to -6, fludarabine IV on days -8 to -4, and anti-CD45 monoclonal antibody IV over 6 hours on days -5 to -2. Patients undergo allogeneic stem cell transplantation on day 0.
After completion of study treatment, patients are followed periodically.